{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:07:37Z","timestamp":1792498057093,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jtha.2023.03.005","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T03:10:34Z","timestamp":1678763434000},"page":"1601-1609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Christina","family":"VanderPluym","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Esteso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Ankola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Hellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Ventresco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan L.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Cetatoiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberlee","family":"Gauvreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Esch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.03.005_bib1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nrcardio.2013.217","article-title":"Thrombosis: congenital heart disease and thrombosis: what do we know?","volume":"11","author":"Monagle","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jtha.2023.03.005_bib2","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1161\/01.cir.0000436140.77832.7a","volume":"128","author":"Giglia","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.03.005_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2019000998","article-title":"DIVERSITY Study Investigators. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children","volume":"135","author":"Brandao","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.03.005_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40119-015-0054-y","article-title":"Current clinical trials on the use of direct oral anticoagulants in the pediatric population","volume":"5","author":"von Vajna","year":"2016","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.jtha.2023.03.005_bib5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (Aristotle) trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.03.005_bib6","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1055\/s-0039-1679938","article-title":"PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric acute lymphoblastic leukaemia (ALL)--rationale and design","volume":"119","author":"O\u2019Brien","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.005_bib7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.03.005_bib8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00246-014-1089-x","article-title":"Utility of a dedicated pediatric cardiac anticoagulation program: the Boston children\u2019s hospital experience","volume":"36","author":"Murray","year":"2015","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jtha.2023.03.005_bib9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2019.08.002","article-title":"Pediatric Heart Network Investigators. A multi-national trial of a direct oral anticoagulant in children with cardiac disease: design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study","volume":"217","author":"Payne","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2023.03.005_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ijlh.13692","article-title":"Using a low\u2013molecular weight heparin\u2013calibrated anti\u2013factor Xa assay to assess the concentration of apixaban and rivaroxaban","volume":"44","author":"von Horn","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2023.03.005_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11239-011-0591-8","article-title":"Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor","volume":"32","author":"Becker","year":"2011","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2023.03.005_bib12","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.005_bib13","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2352-3026(20)30043-0","article-title":"Are controlled trials of anticoagulation in children feasible?","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.03.005_bib14","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2022.09.031","article-title":"Edoxaban for thromboembolism prevention in pediatric patients with cardiac disease","volume":"80","author":"Portman","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2023.03.005_bib15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2023.03.005_bib16","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bcp.12541","article-title":"Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor","volume":"79","author":"Frost","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2023.03.005_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jgs.16193","article-title":"Prevalence and knowledge of potential interactions between over-the-counter products and apixaban","volume":"68","author":"Tarn","year":"2020","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jtha.2023.03.005_bib18","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/bcp.13561","article-title":"Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation","volume":"84","author":"Ueshima","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2023.03.005_bib19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.siny.2011.07.007","article-title":"Developmental haemostasis: secondary haemostasis","volume":"16","author":"Monagle","year":"2011","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1016\/j.jtha.2023.03.005_bib20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1538-7836.2011.04584.x","article-title":"Perinatal and Paediatric Haemostasis Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Developmental hemostasis: recommendations for laboratories reporting pediatric samples","volume":"10","author":"Ignjatovic","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.005_bib21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1055\/s-0031-1297162","article-title":"The coagulation system in children: developmental and pathophysiological considerations","volume":"37","author":"Ignjatovic","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2023.03.005_bib22","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/jth.15677","article-title":"Monitoring of direct oral anticoagulants plasma levels for secondary stroke prevention","volume":"20","author":"Siedler","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.005_bib23","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jth.14001","article-title":"Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants","volume":"16","author":"Testa","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.03.005_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00228-022-03280-8","article-title":"Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study","volume":"78","author":"Nosal","year":"2022","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623002325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623002325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:39:01Z","timestamp":1761536341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623002325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1538783623002325"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.03.005","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}